Foot Ankle Spec. 2025 Jul 20:19386400251355656. doi: 10.1177/19386400251355656. Online ahead of print.
ABSTRACT
BackgroundThis study aims to quantify how well midfoot and transverse tarsal joint arthritis can be treated nonoperatively with fluoroscopic-guided injections.
METHODS: We reviewed the records of 132 patients (155 feet) diagnosed with midfoot arthritis between 2015 and 2019, who received conservative management via periodic fluoroscopic-guided steroid injections. Patients were told to follow-up as needed after the injection.
RESULTS: There was a 94.2% success rate of treating midfoot and transverse tarsal joint osteoarthritis via fluoroscopic-guided corticosteroid injections. On average, each foot received 3.1 (range, 1-21) injections, which did not differ between cohorts (operative = 3.9, nonoperative = 3.0; P = .147). Patients with higher pretreatment Pain Catastrophizing Scale (PCS) scores in Magnification (P = .046), Helplessness (P = .002), and Total (P = .003) subsections were more likely to undergo surgery. Patients diagnosed with depression were more likely to receive more total injections (depression = 4.3, nondepression = 2.9, P = .046) over a greater injection duration (depression = 22.2 months, nondepression = 11.4 months, P = .046).
CONCLUSIONS: Overall, fluoroscopic-guided injections are effective nonoperative treatment of midfoot and transverse tarsal joint arthritis.
LEVEL OF EVIDENCE: Level III, Retrospective cohort study.
PMID:40684371 | DOI:10.1177/19386400251355656
Recent Comments